全链条支持创新：中国促进生物医药产业发展新政及其影响-英_28页_5mb

Summary of "Full-Chain Support for Innovation" and Its Implications for the Chinese Biopharma Industry

Core Content

The Chinese biopharma industry has experienced rapid development over the past decade, becoming a strategic sector for economic growth and public welfare. However, in recent years, the industry has faced challenges such as economic slowdown, a cooling capital market, and external uncertainties like global economic conditions and regulatory changes. In response, the central government introduced the "Full-Chain Support for Innovation" policy in 2024, aiming to provide comprehensive support across the entire value chain of the biopharma sector, from R&D to commercialization. This policy is being implemented through both national and local measures, offering a more integrated and supportive framework for industry players.

Main Trends and Changes in the Industry

1.1.1 Overall Scale of the Industry

• The Chinese biopharma industry grew rapidly until 2021, then entered a downturn in 2022, with a gentle recovery observed in 2024.
• The industry's scale is measured by operating income of scaled biopharma enterprises.

1.1.2 Fundraising Trends

• There has been a sharp decline in fundraising events and amounts for life science and health care (LSHC) companies, both in IPO and non-IPO financing.
• The number and size of IPOs for Chinese LSHC companies have decreased significantly from 2022 to 2024Q2.

1.1.3 External Uncertainties

• Global economic slowdown and adverse legislation (e.g., BIOSECURE Act in the US) have impacted Chinese biopharma companies.
• There is cautious optimism due to signs of global inflation relief and expected interest rate declines, along with China's economic stimulus measures.

1.2.1 R&D Pipeline Growth

• The size of China's active R&D pipeline has increased substantially over the past decade.
• China has become the second-largest market for innovative drug development, showing strong R&D capabilities.

1.2.2 IND and NDA Approvals

• There has been a notable increase in the number of IND and NDA submissions and approvals for innovative drugs.
• This trend indicates a solid foundation for the future growth of the Chinese innovative drug market.

1.2.3 R&D Spending Stability

• Chinese listed biopharma companies have maintained relatively stable R&D expenditure as a percentage of revenue, even during industry downturns.
• This stability is crucial for preserving existing pipelines and fostering new innovations.

1.2.4 Therapeutic Area Financing and New Technologies

• Financing in specialized therapeutic areas such as small molecules, antibodies, and drug delivery has been on the rise.
• AI and other emerging technologies are creating new opportunities for innovation in the industry.
• The proportion of AI-related investment events in the Chinese biopharma financing market increased from 7% in 2023 to over 8% by mid-2024.

Government Measures: Full-Chain Support for Innovation

2.1 National Strategies

• The 2024 Government Work Report highlighted the importance of innovative drug development as a future industry.
• The State Council approved an Implementation Plan for Full-Chain Support for Innovative Drugs, emphasizing support across the entire innovation chain, including basic science, financing, drug approval, insurance, and pricing.
• Key areas of support include financial incentives, talent development, AI integration, and streamlined approval processes.

2.2 Local Policies

• Multiple local governments have issued detailed full-chain support policies, effective from April to October 2024.
• These policies include:
  • Business environment improvement: Streamlined EIA processes, financial support, and standardized manufacturing space.
  • CXOs support: Financial subsidies for contract research organizations (CROs).
  • Public service: Legal and IP support, and issue-resolution mechanisms.
  • Talent attraction: Subsidies for top scientists and assistance in applying for talent projects.
  • Financing support: Government investment via FOF, CVC encouragement, and M&A fund establishment.
  • Credit support: Interest discounts and increased guaranteed amounts for small and high-tech enterprises.

Key Aspects of Full-Chain Support Policies

Industry Strategies

3.1 Multinational Companies (MNCs)

• Innovative Product Introduction: MNCs are focusing on introducing mature products into China but are also accelerating new product launches due to faster approval processes.
• Local R&D Partnerships: MNCs are forming partnerships with local companies to conduct trials and share commercialization profits.
• M&A Activities: Leading MNCs are acquiring local biopharma companies to enhance their pipelines and expand their presence in China.
• Supply Chain Localization: MNCs are considering local sourcing and production to reduce costs and improve supply chain sustainability.

3.2 Local Chinese Biopharma Companies

• Proactive Policy Engagement: Companies are actively seeking and negotiating for policy benefits that align with their R&D strategies.
• Pipeline Expansion: They are increasing investments in R&D, expanding their pipelines, and developing first-in-class (FIC) products.
• Clinical Trial Advancement: There is a notable increase in the number of clinical trials and pipelines advancing to clinical stages.
• Utilizing Local Support: Companies are leveraging local policies for financial, talent, and operational support to enhance their competitiveness.

Outlook

• The "Full-Chain Support for Innovation" policy is expected to create a more supportive ecosystem for the biopharma industry.
• Biopharma industrial parks (BPIPs) are playing a key role in implementing these policies, providing integrated support for R&D, trials, and commercialization.
• With the continued growth in R&D capabilities and the implementation of supportive policies, the Chinese biopharma industry is positioned for recovery and long-term development.

Conclusion

The "Full-Chain Support for Innovation" policy represents a significant shift in the way the Chinese government supports the biopharma sector, offering a comprehensive and integrated approach. This policy is expected to benefit both multinational and local companies, helping them navigate through current challenges and capitalize on new opportunities. The combination of national and local measures, along with the industry's own strategic initiatives, is likely to drive sustainable growth and innovation in the Chinese biopharma market.